TRIM33 and interstitial lung disease: The burden of morbidity stems not only from muscle weakness but also from interstitial lung disease (ILD), calcinosis (notably in juvenile disease), and cancer-associated risks that peak within several years of disease onset and are highest in anti-TIF1-γ positive patients.